Promoter methylation signatures of BRCA2 and TP53 genes in the serum of some breast cancer patients attending radiotherapy clinic in Lagos, Nigeria

Titilola Samuel; Babatunde James; Ahmed Adara-Ali; Yetunde Fayoda; Mym Habeeb

doi:10.1530/endoabs.38.P174

P174

Prev Next

Section Contents Cite

Endocrine Abstracts (2015) 38 P174 | DOI: 10.1530/endoabs.38.P174

SFEBES2015 Poster Presentations Neoplasia, cancer and late effects (31 abstracts)

Promoter methylation signatures of BRCA2 and TP53 genes in the serum of some breast cancer patients attending radiotherapy clinic in Lagos, Nigeria

Titilola Samuel , Babatunde James , Ahmed Adara-Ali , Yetunde Fayoda & Mym Habeeb

Err

Author affiliations

College of Medicine, University of Lagos, Idi-araba, Lagos, Nigeria.

The prevalence of new cases of cancer in developing countries even though less than the developed countries have greater mortality rate, due to lack of access to treatment and early detection of the disease. Epigenetic alterations in BRCA2 and TP53, such as DNA methylation, maybe an effective approach in diagnosis, prognosis and therapy in breast cancer. This study examines the DNA methylation signature of BRCA2 and TP53 in Nigerian breast cancer patients. In this study, thirty seven (37) DNA samples were obtained of which 14 samples with Invasive Ductal Carcinoma (IDC) were assessed by methylation specific PCR and then observed by agarose gel electrophoresis. The methylation analysis shows that there were 8 (57.14%) of the 14 patients with methylated BRCA2 and 11 (78.57%) of 14 patients with methylated TP53 promoter region. This study shows a promising development for a blood - based epigenetics diagnostic approach in detecting breast cancer in Nigeria patients, but further work is required to establish the efficacy, as well as exploring the prognostic and therapeutic values.